Return to search

Silverback Therapeutics nabs $78.5m Series B

Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing.

Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing. U.S. Venture Partners led the round.

Source: Press Release